Doctor Mattia Galli

Doctor Mattia Galli

Sapienza University of Rome, Rome (Italy)

Member of:

Clinical and interventional Cardiologist PhD candidate at Catholic University of the Sacred Heart, Rome, Italy Former Senior Reserch Fellow at University of Florida COllege of Medicine-Jacksonville, Florida, United States

Presentations Articles

Comparative effects of different antiplatelet strategies in carriers of CYP2C19 loss-of-function alleles: a network meta-analysis

Event: ESC Congress 2024

Topic: Antiplatelet Drugs

Session: Pharmacogenomics, cardio-omics, and cardiovascular drugs

Access

P2Y12 inhibitor monotherapy after short DAPT in acute coronary syndrome: a systematic review and meta-analysis

Event: ESC Congress 2024

Topic: Antiplatelet Drugs

Session: Antiplatelet therapy: novel approaches for acute coronary syndrome and percutaneous coronary intervention

Access

Mortality with bivalirudin plus a high-dose infusion versus heparin in patients with acute coronary syndrome

Event: ESC Congress 2023

Topic: Anticoagulants

Session: Antithrombotic therapy in acute coronary syndromes and PCI

Access

Pharmacodynamic and pharmacokinetic profiles associated with switching from cangrelor to prasugrel in patients undergoing percutaneous coronary intervention: the SWAP-6 study

Event: ESC Congress 2023

Topic: Antiplatelet Drugs

Session: Antithrombotic therapy in acute coronary syndromes and PCI

Access

Factor XI inhibitors in early clinical trials: a meta-analysis

Event: ESC Congress 2023

Topic: Anticoagulants

Session: Oral anticoagulation: minimising bleeding

Access

Acetylsalicylic acid challenge or desensitization in sensitive patients with cardiovascular disease

Event: ESC Congress 2023

Topic: Antiplatelet Drugs

Session: Current and novel antiplatelet therapy in cardiovascular disease

Access

Revascularization strategies versus optimal medical therapy in chronic coronary syndrome: a systematic review and network meta-analysis

Event: ESC Congress 2022

Topic: Coronary Arteries

Session: Epidemiology and artificial intelligence

Access

Efficacy and safety of dual pathway inhibition in patients with cardiovascular disease

Event: ESC Congress 2021 - The Digital Experience

Topic: Antiplatelet Drugs

Session: Congress committee e-posters choice in pharmacology and pharmacotherapy

Access

ESC 365 is supported by

Explore sponsored resources

Doctor Mattia Galli

Biography

Contributor content

Comparative effects of different antiplatelet strategies in carriers of CYP2C19 loss-of-function alleles: a network meta-analysis

P2Y12 inhibitor monotherapy after short DAPT in acute coronary syndrome: a systematic review and meta-analysis

Mortality with bivalirudin plus a high-dose infusion versus heparin in patients with acute coronary syndrome

Pharmacodynamic and pharmacokinetic profiles associated with switching from cangrelor to prasugrel in patients undergoing percutaneous coronary intervention: the SWAP-6 study

Factor XI inhibitors in early clinical trials: a meta-analysis

Acetylsalicylic acid challenge or desensitization in sensitive patients with cardiovascular disease

Revascularization strategies versus optimal medical therapy in chronic coronary syndrome: a systematic review and network meta-analysis

Efficacy and safety of dual pathway inhibition in patients with cardiovascular disease

ESC 365 is supported by

Doctor Mattia Galli Follow

Biography

Contributor content

Comparative effects of different antiplatelet strategies in carriers of CYP2C19 loss-of-function alleles: a network meta-analysis

P2Y12 inhibitor monotherapy after short DAPT in acute coronary syndrome: a systematic review and meta-analysis

Mortality with bivalirudin plus a high-dose infusion versus heparin in patients with acute coronary syndrome

Pharmacodynamic and pharmacokinetic profiles associated with switching from cangrelor to prasugrel in patients undergoing percutaneous coronary intervention: the SWAP-6 study

Factor XI inhibitors in early clinical trials: a meta-analysis

Acetylsalicylic acid challenge or desensitization in sensitive patients with cardiovascular disease

Revascularization strategies versus optimal medical therapy in chronic coronary syndrome: a systematic review and network meta-analysis

Efficacy and safety of dual pathway inhibition in patients with cardiovascular disease

ESC 365 is supported by

Doctor Mattia Galli